Stilla Technologies expands its U.S. presence through a strategic distribution relationship with Avantor and introduces advanced content offerings

Stilla, a pioneer in genomics and digital PCR, is excited to announce its expansion into the United States through a strategic distribution relationship with Avantor, a global leader in life sciences and advanced technology solutions.

With this development, Stilla’s comprehensive portfolio of digital PCR products will now be readily available to customers across the United States, further enhancing Avantor’s core genomics portfolio. This expansion facilitates the distribution of Stilla’s cutting-edge solutions through Avantor’s dedicated team of life sciences specialists, streamlining access for both researchers and clinicians.

Kerri McWeeny, GM North America for Stilla, expressed enthusiasm about this collaboration, stating: “This collaboration marks an significant milestone for Stilla in its penetration of the U.S. market. With Avantor’s support, we are well-positioned to achieve our biopharmaceutical, applied testing and academic goals while enhancing our applications to better serve our customers.”

Moreover, Stilla is proud to announce the expansion of its content offering to meet the evolving needs of its customers. With a focus on cell and gene therapy, biopharmaceutical quality control, infectious diseases and applied testing, Stilla aims to provide comprehensive solutions to critical challenges in research and diagnostics.

Dr. Afif Abdel Nour, Vice President of Global Marketing at Stilla, reiterated the company’s commitment to advancing precision medicine through innovation, stating: “At Stilla, we are committed to driving advancements in precision medicine through continuous innovation. Our expanded sales force, global presence and enhanced product offering underscore our unwavering support of our customers and our commitment to expanding the boundaries of molecular diagnostics.

In related news, a recent study by Meierrieks et al reported groundbreaking findings regarding the titration of AAV in clarified crude cell lysate. The study compared various dPCR methods with Stilla’s Crystal Digital method^® PCR technology using Ruby Chip turns out to be one of the best technologies.

Crystal Digital^® PCR showed exceptional results and minimal coefficient of variation (CV) with only 5 µl of total volume and 1 µl of sample. This remarkable performance highlights the Ruby chip’s potential for precise and reliable AAV titration, representing a significant advancement in molecular diagnostics.